共 50 条
- [31] First-in-human phase I study of an oral HSP9O inhibitor, TAS-116, in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Yanagitani, NorikoHoriike, AtsushiKitazono, SatoruOhyanagi, FumiyoshiKondo, ShunsukeShimomura, AkihikoFujiwara, YutakaDoi, ToshihikoKuboki, YasutoshiKawazoe, AkihitoShitara, KoheiOhno, IzumiBanerji, UdaiSundar, RaghavOhkubo, ShuichiHuang, Jerry M.Nishio, MakotoYamamot, Noboru
- [32] A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Mahalingam, DevalingamShaheen, Montaser F.Sarantopoulos, JohnWeitman, StevenGiovanella, Beppino C.Cao, ZhisongCoil, DouglasMarkides, ConstantineLiu, LucyVerschraegen, Claire F.
- [33] A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dumbrava, Ecaterina ElenaKennon, Amber MichelleBalema, Wintana A.Lim, ChaeminVempati, SridharStergiopoulos, SotiriosRichardson, Debra L.
- [34] First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts.CANCER RESEARCH, 2013, 73 (08)Saleh, MansoorPapadopoulos, KyriArabnia, AlirezaPatnaik, AmitaStein, Robin M.Cattaneo, FedericaAbbadessa, GiovanniGreenberg, JonathanWarren, StephenTolcher, Anthony
- [35] Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Patnaik, AmitaMorgensztern, DanielMantia, CharleneTannir, Nizar M.Harshman, Lauren C.Hill, JonathanWhite, KerryChung, Jou-KuBowers, BethSciaranghella, GaiaLee, BenjaminChoueiri, Toni K.Smith, Lon S.Naing, Aung
- [36] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239Friedman, ClaireAscierto, PaoloDavar, DiwakarO'Hara, MarkShapira-Frommer, RonnieDallos, MatthewKhemka, VivekJames, LeeFischer, BruceDemes, ShilpaLi, LiKozicki, MartinRavindran, PalanikumarXu, KeKollia, GeorgiaShoukry, JacquelineYunan, MonaMassey, AshishGutierrez, Martin
- [37] First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Piha-Paul, Sarina AnneXu, BingheRaghav, Kanwal Pratap SinghMeric-Bernstam, FundaJanku, FilipDumbrava, Ecaterina ElenaFu, SiqingKarp, Daniel D.Ahnert, Jordi RodonConley, Anthony PaulMott, FrankAjani, Jaffer A.Hong, David S.Fan, YingPeng, PengLevin, Wendy J.Ngo, BrendaRu, Qinhua CindyWu, FrankJavle, Milind M.
- [38] Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Tolcher, Anthony W.Carvajal, Richard D.El-Khoueiry, Anthony B.Feliu, Waldo OrtuzarZang, HongAncukiewicz, MarekShapiro, IrinaStrauss, James Fredric
- [39] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Demetri, George D.Luke, Jason J.Hollebecque, AntoinePowderly, John D.Spira, Alexander I.Subbiah, VivekLai, Dominic W.Yue, HuibinKasichayanula, SreeneeranjGulbranson, ScottPurcell, JamesMyzak, MelindaRobinson, RandyVillalobos, Victor ManuelTolcher, Anthony W.
- [40] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Sharma, ManishKuboki, YasutoshiCamidge, D. RossPerets, RuthSommerhalder, DavidYamamoto, NoboruBar, JairParikh, ApurvasenaLi, RuiThiele, Gladys MorrisonAristide, Martha Raluca NeaguFreise, Kevin JayPowderly, John D.